BioNTech SE (BNTX) Non-Current Deffered Revenue (2018 - 2024)

BioNTech SE has disclosed Non-Current Deffered Revenue across 7 years of filings, most recently posting $195.6 million for Q4 2024.

• Non-Current Deffered Revenue for Q4 2024 came in at $195.6 million, down 54.39% year-over-year; the trailing twelve-month figure through Dec 2024 was $195.6 million (down 54.39% YoY), and the FY2024 annual result was $195.6 million, down 54.39% from the prior year.
• Non-Current Deffered Revenue came in at $195.6 million for Q4 2024 at BioNTech SE, down from $428.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $428.8 million in Q4 2023 to a low of $10.3 million in Q4 2021.
• The 5-year median for Non-Current Deffered Revenue is $85.7 million (2020), against an average of $153.9 million.
• Across the five-year window, Non-Current Deffered Revenue tumbled 87.99% in 2021 and jumped 768.29% in 2023, its largest moves.
• BioNTech SE's Non-Current Deffered Revenue stood at $85.7 million in 2020, then sank by 87.99% to $10.3 million in 2021, then jumped by 379.62% to $49.4 million in 2022, then surged by 768.29% to $428.8 million in 2023, then plunged by 54.39% to $195.6 million in 2024.
• The last three Non-Current Deffered Revenue figures came in at $195.6 million (Q4 2024), $428.8 million (Q4 2023), and $49.4 million (Q4 2022), per Business Quant data.